Impact of maintenance therapy using a half dose of the bacillus Calmette–Guérin Tokyo strain on recurrence of intermediate and high-risk nonmuscle invasive bladder cancer: a retrospective single-center study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2490
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Impact of maintenance therapy using a half dose of the bacillus Calmette–Guérin Tokyo strain on recurrence of intermediate and high-risk nonmuscle invasive bladder cancer: a retrospective single-center study ; volume:20 ; number:1 ; day:9 ; month:12 ; year:2020 ; pages:1-8 ; date:12.2020
BMC urology ; 20, Heft 1 (9.12.2020), 1-8, 12.2020
- Creator
-
Koguchi, Dai
Matsumoto, Kazumasa
Hirayama, Takahiro
Moroo, Shigetaka
Kobayashi, Momoko
Katsumata, Hiroki
Ikeda, Masaomi
Iwamura, Masatsugu
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12894-020-00766-4
- URN
-
urn:nbn:de:101:1-2021011715430787843558
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:39 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Koguchi, Dai
- Matsumoto, Kazumasa
- Hirayama, Takahiro
- Moroo, Shigetaka
- Kobayashi, Momoko
- Katsumata, Hiroki
- Ikeda, Masaomi
- Iwamura, Masatsugu
- SpringerLink (Online service)
Other Objects (12)
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
Growth inhibition of HeLa cell by internalization of Mycobacterium bovis Bacillus Calmette-Guérin (BCG) Tokyo
Nadofaragene firadenovec in high-risk Bacillus Calmette Guérin unresponsive non-muscle invasive bladder cancer: a profile of its use
Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
Post-Bacille Calmette–Guerin surveillance for non-muscle invasive bladder cancer: do random biopsies offer an advantage?
Durch Bacillus Calmette-Guerin induzierte Tuberkulose
Correction to: Nadofaragene firadenovec in high-risk Bacillus Calmette Guérin unresponsive non-muscle invasive bladder cancer: a profile of its use
Bacille Calmette-Guérin Supply Disruption Emphasizes the Importance of Stewardship
Low-dose Bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: a Markov model
Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
Bekämpfung der Tuberkulose: Schutzimpfung mit Bacillus Calmette-Guérin (BCG)
Immunologic aspects of patients with disseminated bacille Calmette-Guerin disease in north-west of Iran
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
Growth inhibition of HeLa cell by internalization of Mycobacterium bovis Bacillus Calmette-Guérin (BCG) Tokyo
Nadofaragene firadenovec in high-risk Bacillus Calmette Guérin unresponsive non-muscle invasive bladder cancer: a profile of its use
Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
Post-Bacille Calmette–Guerin surveillance for non-muscle invasive bladder cancer: do random biopsies offer an advantage?
Durch Bacillus Calmette-Guerin induzierte Tuberkulose
Correction to: Nadofaragene firadenovec in high-risk Bacillus Calmette Guérin unresponsive non-muscle invasive bladder cancer: a profile of its use
Bacille Calmette-Guérin Supply Disruption Emphasizes the Importance of Stewardship
Low-dose Bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: a Markov model
Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
Bekämpfung der Tuberkulose: Schutzimpfung mit Bacillus Calmette-Guérin (BCG)
Immunologic aspects of patients with disseminated bacille Calmette-Guerin disease in north-west of Iran
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
Growth inhibition of HeLa cell by internalization of Mycobacterium bovis Bacillus Calmette-Guérin (BCG) Tokyo
Nadofaragene firadenovec in high-risk Bacillus Calmette Guérin unresponsive non-muscle invasive bladder cancer: a profile of its use
Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
Post-Bacille Calmette–Guerin surveillance for non-muscle invasive bladder cancer: do random biopsies offer an advantage?
Durch Bacillus Calmette-Guerin induzierte Tuberkulose
Correction to: Nadofaragene firadenovec in high-risk Bacillus Calmette Guérin unresponsive non-muscle invasive bladder cancer: a profile of its use
Bacille Calmette-Guérin Supply Disruption Emphasizes the Importance of Stewardship
Low-dose Bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: a Markov model
Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
Bekämpfung der Tuberkulose: Schutzimpfung mit Bacillus Calmette-Guérin (BCG)